Oral antiretroviral chemoprophylaxis: Current status

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 514-519

  Baeten, Jared ^a   Celum, Connie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

emtricitabine; HIV prevention; preexposure prophylaxis; sexual HIV 1 transmission; tenofovir

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; TENOFOVIR DISOPROXIL;

ANTIVIRAL RESISTANCE; BONE DEMINERALIZATION; BONE DENSITY; CHEMOPROPHYLAXIS; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE HOMOSEXUAL; NAUSEA; PATIENT COMPLIANCE; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; TUBULAR DYSFUNCTION; VERTICAL TRANSMISSION;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; ORGANOPHOSPHONATES;

EID: 84868486363     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283582d30     Document Type: Review

References (31)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493- 505.
2. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591- 601.
3. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197- 1199.
4. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.
5. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Translat Med 2010; 2:14ra4.
6. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009; 83:10358-10365.
7. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006; 194:904-911.
8. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271- 2281.
9. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
10. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. 2012. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012. [Epub ahead of print]
11. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. 2012. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012. [Epub ahead of print]
12. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012. [Epub ahead of print]
13. National Institute of Allergy and Infectious Diseases (NIAID). 2011. NIH modifies 'VOICE' HIV prevention study in women. http://www.nih.gov/news/health/ sep2011/niaid-28.htm. [Accessed 30 July 2012]
14. National Institute of Allergy and Infectious Diseases (NIAID). 2011. NIH discontinues tenofovir vaginal gel in 'Voice' HIV prevention study. http://www.nih.gov/news/health/nov2011/niaid-25.htm. [Accessed 30 July 2012]
15. Martin M, Vanichseni S, Suntharasamai P, et al. Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS ONE 2011; 6:e25127.
16. Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral preexposure prophylaxis for HIV-1 prevention. PLoS One 2011; 6:e25828.
17. Bangsberg D, Haberer J, Psaros C, et al. High adherence and high effectiveness observed in HIV discordant couples: Partners PrEP Study, adherence monitoring and counseling substudy. Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA. (Abstract 1067); 2012.
18. Donnell D, Baeten J, Hendrix C, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA. (Abstract 30); 2012.
19. Liu A, Vittinghoff E, Irby R, Mulligan K, Sellmeyer D, et al. BMD loss in HIV- men participating in a TDF PrEP clinical trial in San Francisco. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA. (Abstract 93); 2011.
20. Mugo N, Celum C, Donnell D, Campbell J, Bukusi E, et al. Pregnancy incidence and birth outcomes in a clinical trial of PrEP: Uganda and Kenya. Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, USA. (Abstract 1060); 2012.
21. Antiretroviral Pregnancy Registry Interim Report, 1 January 1989 through 31 July 2011. http://www.apregistry.com/forms/interim-report.pdf. [Accessed 30 July 2012]
22. Anderson P, Meditz A, Zheng J-H, Predhomme J, Klein B, et al. Cellular pharmacology of tenofovir and emtricitabine in blood, rectal, and cervical cells from HIV-volunteers. Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA. (Abstract 587); 2012
23. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
24. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
25. Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data metaanalysis. PLoS Med 2011; 8:e1000416.
26. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Medicine 2011; 8:e1001123.
27. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012; 156:541-550.
28. Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of preexposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012; 54:1504-1513.
29. HIV Prevention Trials Network. HPTN 067: The ADAPT Study - a phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovir disoproxil fumarate preexposure prophylaxis (PrEP). 2011. http://www.hptn.org/research-studies/hptn067.asp. [Accessed 30 July 2012]
30. The IPERGAY Study. 2012. http://www.ipergay.fr/. [Accessed 30 July 2012]
31. Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception preexposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS 2010; 24:1975-1982.